Wilms tumor is the most common malignant tumor of the kidney in childhood. Discoveries surrounding its pathogenesis have provided important conceptual advances in knowledge of both oncogenesis and renal development. Until recently, knowledge of the genetic underpinnings of Wilms tumor was limited largely to aberrations of WT1, abnormalities of 11p15 methylation, and Wnt-activating mutations involving CTNNB1 and AMER1 (ref. 1) Recent comprehensive genomic analyses of Wilms tumor identified novel mutations involving miRNAprocessing genes DROSHA, DGCR8, and DICER1; renal developmental genes SIX1 and SIX2, and MYCN 2-4 . Despite these efforts, recurrent driver mutations were not identified in most Wilms tumors. The US National Cancer Institute's Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative enabled comprehensive characterization of a discovery set of 117 high-risk Wilms tumor cases, defined as having either favorable histology (FHWT) that relapsed or diffuse anaplasia (DAWT, characterized by the presence of enlarged, hyperchromatic nuclei and atypical mitoses) 5 . The variant frequency in a population-based set of Wilms tumor cases was then established in a validation set of 651 tumors (533 FHWT and 118 DAWT) consistently clinically treated in the National Wilms Tumor Study-5 (NWTS-5) clinical trial. Thus far, this effort has reported recurrent mutations involving DROSHA, DGCR8, XPO5, DICER, SIX1, and SIX2 in FHWT 6 , novel mutations involving MLLT1 in FHWT 7 , and the clinical significance of TP53 abnormalities in DAWT 8 . The current study provides the consolidated data for all TARGET Wilms tumors (FHWT and DAWT), identifying additional recurrent novel somatic and germline mutations, recurrent copy number changes (including gain of LIN28B and loss of MIRLET7A), and global mRNA and miRNA expression as well as DNA methylation patterns. Through the integration of these analyses, we propose a genetic framework for Wilms tumor within the context of early renal development. 
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A r t i c l e s (mean of 13.6 and 19.7 variants per patient in FHWT and DAWT, respectively). All verified somatic missense and in-frame variants predicted to be damaging and not identified in 1000 Genomes series 3, all known COSMIC mutations, and all verified nonsense and frameshift mutations are provided in Supplementary Table 1 ; variants in genes recurrently involved, and variants involving other selected genes, are provided in Table 1 . Genes most affected were CTNNB1, DGCR8, DROSHA, MLLT1, MYCN, SIX1, SIX2, TP53, WT1, and AMER1, with frequencies in keeping with previous publications. An exception was WT1, which showed fewer variants, owing to restriction of the discovery set to high-risk cases (the majority of Wilms tumor with WT1 mutation are not high risk) 1 . Three tumors had MAX mutation c.179G>A, encoding p.Arg60Gln (GenBank NM_002382.4), previously reported in a single Wilms tumor 3 . Genes with variants in more than two tumors and not previously reported in Wilms tumor include BCOR (n = 5, all truncating), NONO (n = 3, encoding either p.Arg75Cys (c. 223C>T; GenBank NM_007363.4) or p.Arg75His (c.224G>A; NM_007363.4)), and ACTB. An additional 16 genes had variants in two Wilms tumors ( Table 1 ). One discovery sample had two somatic DICER1 mutations-one truncating and one missense (discussed below).
We performed bioinformatic analysis for structural variants on 80 tumors analyzed by whole-genome sequencing (WGS). Subsequent DNA copy number analysis or mRNA-seq verified 54 deletions, 17 tandem duplications, and 11 junctions (Supplementary Table 2 ). The deletions varied from 229 to 679 bp (average 412 bp), and most occurred within short interspersed repeats and were randomly distributed across the genome. Deletions were identified involving WT1 (n = 2), TP53 (n = 3), AMER1 (n = 3), DIS3L2 (n = 1), and ACTB (n = 1). Conversely, 10 of 17 duplications encompassed the MYCN locus, 9 of which involved NBAS; all showed MYCN gain by copy number analysis.
Germline mutations in discovery set
We evaluated the paired normal samples for germline variants within genes identified and listed in Table 1 (Supplementary Table 1 ). Germline variants likely to be of clinical significance (defined as verified nonsense or frameshift variants and missense single nucleotide variants (SNVs) categorized by ClinVar as likely pathogenic or pathogenic) were identified in XPO5 (n = 1), TP53 (n = 1), WT1 (n = 1), CHEK2 (n = 1), and PALB2 (n = 1). Additional germline novel SNVs predicted to be damaging by ≥4 predictors and in-frame variants predicted to be damaging by PROVEAN (Online Methods) included PALB2 (n = 2), CHEK2 (n = 1), HDAC4 (n = 1), WT1 (n = 1), and EP300 (n = 1). Additional germline SNVs of unclear significance were identified in DICER1 (two in the same patient), CHEK2, DROSHA, NF1, ARID1A, and MLLT1. Of note was a germline splice site variant in DIS3L2, encoding a let-7 miRNA processing factor responsible for Perlman syndrome 9 .
Mutations in validation set tumor samples
We performed targeted capture sequencing for 37 genes identified from the discovery set (Table 1 ) on the validation set of 651 Wilms tumors. The discovery and validation sets are both based on NWTS-5 samples and are not independent (Online Methods). Therefore, all frequencies refer only to the validation set. Overall, 440 of 651 tumors carried mutations in the genes analyzed that were predicted to be damaging ( Table 1 , Online Methods, and Supplementary Table 3) . Our experience with the discovery set suggests that the remaining tumors either had driver mutations in genes not detected as recurrent in the discovery set and therefore not analyzed in the validation set, or had copy number gains or losses involving important genes (discussed below). Mutation distribution by histology and concurrent mutations are provided in Supplementary Table 4 . Mutations in TP53 were significantly associated with DAWT histology (56/118 DAWT and 9/533 FHWT; Fisher's exact test P < 1 × 10 −10 ). These were identified concurrently with all high-frequency mutations (Table 1) , most often with a lower allelic fraction, consistent with the role of TP53 as a secondary mutation in Wilms tumor 8, 10 . CTNNB1 was the most commonly mutated gene, with 95 mutations (62 and 20 involving exons 3 and 8, respectively) in 88 validation set tumors. Five tumors shared a pair of variants involving positions 41266133 (c.130C>G, GenBank NM_001904.3; COSMIC COSM17661) and 41266136 (c.133T>C, GenBank NM_001904.3: c.133T>C; COSMIC 5663); both variants occurred on the same strand, suggesting they resulted from the same mutational event. Mutations in CTNNB1 were significantly associated with favorable histology (86/533 FHWT and 2/118 DAWT; Fisher's exact test P = 2.2 × 10 −6 ). Analysis of genes concurrently mutated (Supplementary Table 4 ) showed significant mutational co-occurrence of WT1 with CTNNB1 (34/88 tumors with CTNNB1 mutation also had WT1 mutation, and 34/46 tumors with WT1 mutation also had CTNNB1 mutation; Fisher's exact test P = 0.0001), as previously reported 11 and of DROSHA with SIX1 or SIX2 mutations (10/67 tumors with DROSHA mutation also had mutation in SIX1 or SIX2, and 10/43 tumors with SIX1 or SIX2 mutations also had DROSHA mutation; Fisher's exact test P = 0.0012). CTNNB1 mutation was concurrent with many recurrent mutations, and all except AMER1 had the same preference for exon 3. In four tumors with CTNNB1 and AMER1 mutations, CTNNB1 exons 3, 7, 9, and 13 were involved. Mutation locations relative to known protein domains are illustrated in Supplementary Figure 1 .
Sixteen validation samples had 21 DICER1 mutations. Wilms tumors containing two DICER1 mutations have been reported 12, 13 ; therefore, DICER1 mutations were examined in detail within the validation set. Only two samples in the validation set (one of which was also in the discovery set) had the truncating DICER1 mutations combined with missense variations in the RNase III domain described in patients with pleuropulmonary blastoma syndrome 14, 15 . The DICER1 RNase III domain encodes a metal-binding site 16 critical for miRNA cleavage. Of the remaining three tumors that had two DICER1 mutations, all had missense variations in the RNase III domain, accompanied by missense variants of unknown significance in either the PAZ domain, the DExD/H domain, or a splice site (Supplementary Table 3 ). Three additional cases had one missense variation in the RNase III domain with high allelic frequencies (0.63, 0.75 and 0.97), suggesting loss of heterozygosity at this locus, similar to a previous report 13 . Therefore, biallelic involvement of DICER1 (either somatic or germline) may be seen in up to 8/651 (1%) of patients with Wilms tumor.
Eight tumors had missense CHEK2 mutations: four were rs17879961 variants (GenBank NM_007194.3, c.470T>C) and were classified as likely pathogenic by ClinVar. Eight PALB2 mutations were identified in eight tumors: two frameshift deletions, two inframe deletions, one nonsense variant, and three SNVs classified as uncertain or likely benign by ClinVar. PALB2 variants were preferentially identified in DAWT (3/533 FHWT and 5/118 DAWT; Fisher's exact test P = 0.006) (Supplementary Table 3 ). Six tumors carried EP300 variants, five with the same germline in-frame deletion identified in the discovery set. The majority of the 19 NF1 variants were missense mutations judged damaging by 2-3 of 5 algorithms and of unclear functional significance by ClinVar. DIS3L2 was not included in the target capture sequencing.
A r t i c l e s
Computational structure analysis Protein structural models of genes with recurrent hotspot mutations not previously analyzed were retrieved from the Protein Data Bank (PDB) or obtained by homology modeling (Supplementary Fig. 2 ). MAX binds DNA as a heterodimer with MYCN or MYCC. Arg60 of MAX, located in the C terminus of the basic helix-loop-helix domain, interacts nonspecifically with the DNA phosphate backbone. Loss of the positive charge due to the p.Arg60Gln substitution is expected to weaken DNA interactions. NONO forms dimers with two RNA-recognition motifs (RRM1 and RRM2) arranged in a particular constellation required for the three-dimensional (3D) recognition of structured RNA substrates 17 . The NONO p.Arg75Cys and p.Arg75His substitutions (located in the hinge region between RRM1 and RRM2) are expected to disrupt the interactions between the two domains, leading to increased flexibility and protein destabilization, and thus may affect RNA recognition. MAP3K4 Gly1366 is located in a tight loop between the second and third β-strand of the kinase domain. Although Gly1366 is more than 20 Å away from the kinase active site, its replacement by arginine may allosterically change or deregulate the kinase activity. Within ACTB (β-actin), all alterations except p.Ile282del (GenBank NM_001101.3, c.846_848delCAT) cluster on the same surface region located toward the barbed, 'plus' end within actin fibers. This region is not directly implicated in F-actin formation but is accessible in F-actin and may constitute a binding site for actin-modulating factors. The p.Ile282del and p.Lys326del (NM_001101.3, c.977_ 979delAGA) alterations are predicted to affect loops implicated in Table 5 ). Gain of 1q was identified in 56/117 tumors, a frequency consistent with previous reports 18, 19 . Gain of 1q was not preferentially concurrent with the mutations listed in Table 1 , consistent with its suspected role as a secondary event. Amplification at 2p24 including MYCN (defined as log 2 segment mean >2.0 and/or presence of structural variants) was identified in 19 tumors (9/78 FHWT and 10/39 DAWT), frequencies similar to those previously reported 20 . Loss of 17p correlated with TP53 mutation as well as loss of 4q and 14q, as previously reported within TARGET tumors 8 . Genes in Table 1 were reviewed for copy gains and losses. Unexpectedly, we identified gain (log 2 mean >0.5) of chromosomal segments containing 6q16, the location of LIN28B, in 29/117 tumors, with 24 showing a log 2 segment mean >1; the mechanism in all cases was gain of the entire chromosome 6. DNA copy changes for the chromosomal locations of MIRLET7A family members showed loss of MIRLET7A1 (9q22) in 6/117 (2/78 FHWT, 4/39 DAWT), MIRLET7A2 (11q24) in 22/117 (13/78 FHWT, 9/39 DAWT), and MIRLET7A3 (22q13) in 26/117 (8/78 FHWT, 18/39 DAWT) (annotated in aggregate for FHWT in Fig. 1 ).
Gene expression analysis
Unsupervised hierarchical analysis of the 76 FHWT with available gene expression data resulted in k = 6 clusters (non-negative matrix factorization (NMF) cophenetic correlation = 0.92). Figure 1 illustrates
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the most common somatic mutations, copy changes, and pathologic features ordered according to the NMF gene expression clustering.
The most common variants showed preferential cluster membership, with LIN28B gain and MIRLET7A loss residing in cluster 1; DROSHA, DGCR8, SIX1, and SIX2 mutations residing in cluster 2; and MLLT1, WT1, CTNNB1, and CTNNB1 mutations residing in clusters 3 and 4. Similarly, blastemal predominant tumors and perilobar nephrogenic rests predominated in cluster 2, and triphasic (mixed) tumors and intralobar nephrogenic rests predominated in clusters 3 and 4. We used gene-set enrichment analysis (GSEA) comparing tumors of each cluster with all other tumors to obtain significantly (P < 5%, false discovery rate (FDR) < 20%) enriched gene lists (Supplementary Table 6 and Fig. 1) . In cluster 1, 1q genes and genes encoding targets of E2F transcription factors, mitotic spindle assembly proteins, and G2/M checkpoint proteins were significantly enriched. E2F3 activation has been reported in Wilms tumors 21 . In cluster 4, a set of genes involved in myogenesis, epithelial-to-mesenchymal transition, and components of the apical junction complex was enriched, in agreement with previous reports showing a subset of high-risk Wilms tumors characterized by low WT1 expression and increased muscle differentiation (most Wilms tumor with low WT1 expression and muscle differentiation are low risk) 1 . Cluster 5 tumors showed enrichment of genes involved in oxidative phosphorylation (Fig. 1) . Examination of representative genes crucial to renal development showed upregulation of preinduction metanephric mesenchyme genes and low expression of post-induction metanephric mesenchyme genes in the majority of Wilms tumors, whereas genes upregulated after Wnt activation (including DKK2, WIF1, AXIN2, CCND1, and MYC) were expressed predominantly in clusters containing Wnt-activating mutations (Fig. 1) . Finally, increased expression of LIN28B correlated with the prevalence of LIN28B DNA copy gain in cluster 1. Increased LIN28B expression was also identified in clusters 3 and 4; notably, Wnt activation has been shown to result in increased mRNA expression of LIN28B 22 . LIN28A was not expressed in most tumors; the functions of LIN28A and LIN28B have been reported to be different 23 .
Global methylation analysis
In 78 discovery FHWTs, unsupervised analysis of methylation probes that significantly correlated with gene expression (unpaired t-test P < 0.05, both negative and positive) resulted in k = 4 clusters (NMF cophenetic correlation 0.965). Tumors with MLLT1 mutations dominated methylation cluster 1, whereas tumors with WT1 and DROSHA or SIX variants were in methylation clusters 2 and 3, respectively ( Supplementary Fig. 3 and Fig. 1) . We identified genes with localized, coordinately differentially methylated islands (Online Methods and Supplementary Table 7) . Differences in methylation of these islands were small, and no clear pattern could be identified. Genes previously reported to have methylation changes in Wilms tumors 24 and the genes in Table 1 showed only isolated probes that correlated with gene expression. The exception was methylation of the ICR1 region of 11p15, which significantly correlated with IGF2 expression (general linear model FDR 9.33 × 10 −18 ). We identified loss of heterozygosity (LOH), loss of imprinting (LOI), and retention of imprinting (ROI) in 35%, 41%, and 23% of the 116 evaluable discovery set tumors, respectively (Figs. 1 and 2a) .
miRNA analysis
Mutations involving miRNA-processing genes in Wilms tumor have been shown to result in significantly decreased miRNAs 3, 6 , particularly let-7a, the miR-200 family, and miR-181. To determine the overall patterns of miRNA expression within Wilms tumors, we performed unsupervised analysis of miRNA-seq done on 78 discovery FHWTs, which resulted in four clusters (NMF cophenetic coefficient = 0.9511) ( Supplementary  Fig. 4 ). Only tumors with MLLT1 mutations clearly clustered (methylation cluster 1). A comparison of miRNA expression between FHWTs with (n = 7) and without (n = 71) MLLT1 mutations showed notable upregulation of mature miR-10a (fold change 3.3) and downregulation of miR-10b (fold change 0.4) (Fig. 2b) . The mir-10 family is localized and regulated with Hox genes and is dysregulated in a variety of cancers 25 . Mature let-7a expression, assessed here by miRNA sequencing and previously by quantitative RT-PCR 6 , was significantly increased in tumors of gene expression clusters 3 and 4 compared with those of clusters 1 and 2 (Fig. 2c) . We were puzzled by the lack of clustering of DROSHA mutant tumors with DGCR8 mutant tumors by miRNA expression analysis. This may be related to the recent recognition of DROSHA functions that extend beyond miRNA processing and include the recognition and cleavage of mRNAs and, potentially, ribosomal RNAs, as well as modification of its own expression [26] [27] [28] .
The above gene expression, methylation, and miRNA analyses performed on FHWT were also performed on the combination of FHWT with DAWT and on DAWT alone. These analyses did not yield further data of biological relevance, probably owing to the inclusion of tumors with TP53 mutation and accompanying genomic instability. 600,000 500,000 400,000 300,000 200,000 100,000 0 800,000 700,000 600,000 500,000 400,000 300,000 200,000 100,000 0
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mir-10b P = 4.2 × 10 A r t i c l e s DISCUSSION Comprehensive sequencing has illustrated that pediatric embryonal neoplasms typically arise after a limited number of genetic aberrations, an observation we confirm in Wilms tumors. In addition, our study shows that Wilms tumors (i) commonly arise through more than one genetic event, (ii) show differences in gene expression and methylation patterns with different genetic aberrations, (iii) have a large number of candidate driver genes, most of which are mutated in <5% of Wilms tumors, and (iv) have recurrent mutations in genes with common functions, with the majority involved in either early renal development or epigenetic regulation (chromatin modifications, transcription elongation, and miRNA).
Early murine progenitor cells actively proliferate under the influence of genes such as Eya1, Six1, Six2, Sall1, and Cited1 and resist Wntdirected differentiation 29, 30 . A segment of this population becomes susceptible to the influence of Wnt9b (secreted by the ureteric bud), resulting in a switch from bivalently modified histones to permissive histone marks on Wnt4, Fgfr8, Pax8, Cdh4, and Lef1; gain of repressive histone marks on renewal genes Six2 and Osr1 (ref. 31); and, ultimately, mesenchymal-to-epithelial transition, known as induction. At least some of these cellular mechanisms are directed by Wt1, which binds the Wnt4 transcription start site and recruits Crebbp and Ep300, proteins involved in histone acetylation 32 . This Wt1-Crebbp-Ep300 protein complex is required for a shift from repressive to active chromatin at the Wnt4 promoter, and for a change in the phosphorylation states of RNA polymerase II, allowing the switch from paused transcription to transcriptional elongation 33 . (CBP and p300 also promote histone H3 acetylation at the WT1 intronic enhancer, thereby increasing WT1 transcription, while HDAC4 represses WT1 transcription 34 .)
Given this context, we demonstrate robust expression of preinduction developmental genes and low expression of post-induction genes in most Wilms tumors, consistent with the expected phenotype of preinduction renal progenitor cells (Fig. 1) . This is consistent with previous studies showing expression of genes characteristic of early renal development within Wilms tumor blastemal cells and within self-renewing human Wilms tumor stem cells 35, 36 . In Wilms tumor, the differentiation arrest is incomplete, allowing lineages to mature in varying proportions 37 . We also demonstrate recurrent mutations in several genes critical for early renal development, including SIX1, SIX2, WT1, EP300, CREBBP, and MYCN, while other mutated genes encode proteins that mediate histone modifications important in renal development (MLLT1, BCOR, MAP3K4, BRD7, and HDAC4) ( Table 1) . Evidence of Wnt signaling is confined largely to Wilms tumors with Wnt-activating mutations. These genetic events are associated with two processes: preservation of the progenitor state (exemplified by clusters 1 and 2) and abnormal induction (exemplified by clusters 3 and 4). For clarity, these two patterns are discussed separately, although the regulatory processes governing the transition from the progenitor state through induction are complex and intertwined.
With regard to preservation of the progenitor state, SIX1 and SIX2 are critical for progenitor renewal. Loss of Six2 leads to epithelial differentiation and rapid exhaustion of nephron progenitors 38 . The overwhelming predominance of p.Gln177Arg alterations in SIX1 and SIX2 in Wilms tumors, the observation that these alterations result in upregulated cell-cycle genes 6 , and the published structural analysis of these alterations 3 , which are thus far specific to Wilms tumor, all indicate that they have an activating function. MYCN also mediates proliferation of nephron progenitor cells through several mechanisms 39, 40 . SIX2 and EYA1 directly bind and dephosphorylate Thr58 of MYCN, preventing MYCN degradation and exit from the cell cycle 41 . We found both MYCN amplification and activating p.Pro44Leu or p.Pro44His alterations (GenBank NM_005378.5, c.131C>T), which have been identified previously in Wilms tumor 6, 20 . Mutations in MAX and NONO may result in cellular impacts similar to those seen with MYCN overexpression. MAX binds DNA as a heterodimer with MYCN or MYCC, and this MYC-MAX transcriptional activator is involved in all known oncogene functions of MYC 42 . The MAX p.Arg60Gln alteration has also been identified in colon cancer, leukemia, and glioma, and lies within the conserved bHLH-Zip domain involved in protein-protein interactions and DNA binding (COSMIC COSM166665). NONO, an RNA-binding protein, binds to MYCN, leading to post-transcriptional upregulation of MYCN mRNA and protein expression 43 .
Mutations involving the miRNA-processing genes also appear to perpetuate the progenitor state. They result in global reduction of mature miRNAs, in particular let-7a, which is a potent mediator of differentiation during early development 3, 5, 6 . Decreased let-7a expression may also result from upregulation of LIN28B, which encodes a protein that specifically binds let-7a pri-and pre-miRNA, preventing their maturation 23, 44, 45 . Gain of LIN28B has been mechanistically tied to Wilms tumor development: overexpression of Lin28b within the preinduction metanephric mesenchyme of mice results in expansion of progenitor cells (due to sustained proliferation and delay of maturation), and formation of Wilms tumor, a process rescued by let-7 overexpression 44 . We observed increased DNA copy number of LIN28B in 25% of Wilms tumor samples and DNA copy loss of let-7a in 46%. Notably, while mutations in miRNA-processing genes were more frequent in gene expression cluster 2, gain of LIN28B and loss of let-7a were more frequent in cluster 1. This separate clustering by gene expression was not accompanied by separate clustering by global miRNA expression. This common pattern of miRNA expression, despite the different pathogeneses, may result from similar direct impacts on a subset of miRNAs (such as let-7a); alternatively, this may reflect common downstream effects on miRNA expression within early renal progenitor cells. The differences in gene expression between clusters 1 and 2 may be due to tumorigenesis during different developmental windows, as suggested by the observation that clusters 1 and 2 show differences in type of precursor lesion (nephrogenic rests) as well as dominant histologic features. These differences will be important to investigate in the future.
With regard to abnormal induction, during murine renal development induction requires binding of Wt1, Crebbp, and p300 on the Wnt4 promoter as well as changes in histone modifications and RNA polymerase II phosphorylation, which result in the switch from paused to transcriptional elongation of Wnt4 (ref. 33) . Notably, clusters 3 and 4 contained the majority of mutations involving WT1 as well as MLLT1, which encodes a key component of the super-elongation complex whose main role is to regulate transcriptional elongation. MLLT1 brings the PTEFb complex (which phosphorylates RNA polymerase II) to the PAF complex (which governs chromatin modifications and is bound to RNA polymerase II), resulting in transcriptional elongation 46 . Aberrations of genes encoding PAF complex components CTR9 and CDC73 are also rare causes of familial Wilms tumor 7 . In addition to WT1, CREBBP, EP300, and MLLT1, other proteins involved in transcriptional elongation whose encoding genes are recurrently mutated in Wilms tumor include MAP3K4, which activates CREBBP 47 , and BRD7, a component of a SWI-SNF chromatin remodeling complex that interacts with EP300 and mediates histone H3 acetylation at Lys9 (H3K9ac), an important permissive modification during renal development 48, 49 . It has been proposed that MLLT1 (and the highly homologous AF9) serve as reader proteins that specifically recognize H3K9ac 50 . Of note, we identified recurrent truncatingmutations in BCOR, which encodes a protein that binds to MLLT1 and results in transcriptional repression 51 . Loss-of-function mutations in BCOR may therefore have the same impact as gain-of-function MLLT1 mutations seen in Wilms tumor. BCOR mutations result in increased H3K4 and H3K36 methylation (a modification characteristic of transcription elongation) accompanied by expression of genes normally silenced in mesenchymal stem cells 52 . Recurrent truncating mutations in the related transcriptional corepressor, BCORL1, were also identified in Wilms tumor. In summary, 30-50% of mutations in Wilms tumors appear to converge upon the process of transcriptional elongation. Investigations of the functional and mechanistic details represent a promising area for future research.
CTNNB1, the gene most commonly mutated in Wilms tumor, encodes a protein crucial for WNT4-and WNT9-mediated induction. After induction, downregulation of CTNNB1 is required for normal nephron differentiation 53, 54 . Therefore, Wnt-activating CTNNB1 mutations in Wilms tumors are likely to result in abnormal induction and/or continued progenitor proliferation. Mutations in AMER1, encoding a protein responsible for the degradation of CTNNB1, may similarly result in Wnt activation 55 . However, the paucity of AMER1 alterations concurrent with WT1 mutations, compared with concurrent CTNNB1 mutations identified in 80% of WT1-mutant Wilms tumors, suggests that AMER1 and CTNNB1 mutations may have different functional activities.
Mutations in FBXW7 have been described in 2/104 post-therapy Wilms tumors and were associated with epithelial differentiation 56 . FBXW7 mutations and small segmental copy losses were not identified in our discovery set. Wilms tumors with exclusive epithelial histology are rare, usually low stage, and seldom relapse when completely resected 57 . Such tumors are therefore not likely to be present in the TARGET discovery set. FBXW7 mutations may also occur as secondary mutations and therefore are more likely to be identified after therapy or in response to therapy.
Germline mutations were identified in at least 10% of patients. These include WT1, TP53, DICER1, and DIS3L2 germline mutations (already recognized in Wilms tumor) as well as variants that predispose to breast cancer, including PALB2 (which rarely results in Fanconi anemia and Wilms tumor 58 ) and CHEK2 (not previously recognized in Wilms tumors). Other novel recurrent germline mutations identified, including EP300 and ARID1A, will require functional validation.
In conclusion, our comprehensive genomic analyses suggest that many different genetic changes converge on a limited number of developmental pathways resulting in oncogenesis. One such pathway is regulated by miRNA biogenesis (which promotes the progenitor state), and another is transcriptional elongation that prevents normal induction. Both rely on the epigenetic regulation of transcription during early renal development, which represents a fruitful area of future research. The large number of genes with driver mutations identified in Wilms tumor, combined with the relatively small number of gene expression patterns, suggests that future studies that attempt to target common processes or pathways may be more efficient than targeting individual gene mutations.
URLs. Oncotator, http://www.broadinstitute.org/oncotator/; PrimerZ, http://genepipe.ncgm.sinica.edu.tw/primerz/beginDesign.do; Gene Set Enrichment Analysis, http://software.broadinstitute.org/gsea/index.jsp.
METhODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METhODS
Study overview. The TARGET initiative supports the long-term maintenance of the data files, methods, and quality-control steps involved in the comprehensive genomic analysis of TARGET samples. All data sets include MIAME-and MINSEQE-compliant MAGE-TAB metadata 59 files (using v1.1 specification supporting both next-generation sequencing and microarrays) and fully describe the methods, specimen-processing details, and quality-control parameters. Studies were performed with the approval of the Ann and Robert H. Lurie Children's Hospital Institutional Review Board.
Clinical samples. Discovery set. All patients registered on the NWTS-5 protocol with obtained informed consent were eligible if sufficient frozen samples from the primary, pre-treatment tumor and normal kidney or peripheral blood were available and if they met the criteria for high risk. This included 78 FHWT patients that relapsed after chemotherapy and 39 DAWT patients showing anaplasia in at least 50% of the slides reviewed centrally, for a total of 117 samples. This sample size is associated with a >99% probability of detecting mutations present in 5% of Wilms tumors.
Validation set. From the 1,473 FHWT patients enrolled in NWTS-5 with available samples, a random sample of 33% was taken. To this group all patients who relapsed were added, resulting in a total of 600 patients, 30% of whom had relapsed. This approach allows for efficient evaluation of molecular markers in a tumor type characterized by a low rate of relapse. The 533 of 600 samples that had sufficient tumor DNA and passed quality control were included. In addition, samples from all patients enrolled in NWTS-5 and classified as DAWT on central pathology review for which tumor DNA that passed quality control was available (118 DAWT samples) were included.
Sequencing. Of the 117 discovery set cases, 80 were characterized by WGS and 37 by whole-exome sequencing (WES). WGS libraries were constructed and sequenced by Complete Genomics, Inc. (CGI) 60 . Sequencing and alignment of reads to the NCBI build 37 reference human genome assembly were performed according to the CGI Cancer Sequencing service analytic pipeline. Somatic, nonsynonymous exonic variants with a somatic score > −10, somatic rank ≥0.1, and Fisher's exact test score ≥13 were retained. Structural variants with discordant mate pair alignments ≥25, successful local de novo assembly, frequency = 0 in the baseline genome set, no overlap with known underrepresented repeats, and length ≥70 for left and right sections, and that occurred within or contained genes were retained. WES was performed on the Illumina HiSeq platform. Variant calling used two approaches, which were then combined, retaining all variants. The first approach applied both ATLAS and SAMtools followed by the SACBE annotation pipeline 61, 62 . In the second approach, the BAM files were independently analyzed using Bambino (version 1.05) 63 . All nonsilent variants from both WGS and WES were combined into a single file and annotated with the Oncotator program (see URLs). Missense variants were classified as polymorphisms (identified within dbSNP build 142), known COSMIC mutations, or novel variants and were assessed by five prediction algorithms: SIFT 64 , PolyPhen (version 2) 65 , dbSNF LR 66 , Mutation Taster 67 , and Mutation Assessor 68 . Variants considered to be damaging were COSMIC mutations, novel SNVs predicted to be damaging by at least two algorithms, SNVs present in dbSNP predicted to be damaging by at least three algorithms, in-frame insertion-deletion variants predicted to be damaging by Provean (version 1.1.3) 69 , and all frameshift and nonsense mutations.
Cases with available tumor mRNA (78 FHWT and 37 DAWT) were characterized by mRNA-seq and miRNA-seq. Libraries were prepared following a strand-specific, paired-end protocol as described 70 . For mRNA analysis, variants were detected on positive-and negative-split BAMs separately and annotated with SnpEff 71 and SnpSift 72 . Normalized fractional read counts were calculated for each exon to quantify gene and exon expression. For miRNA analysis, reads aligning to known miRNAs in miRBase v20 were summed and normalized to 1 million miRNA-aligned reads.
Target capture DNA sequencing (validation set). Biologically relevant genes that were recurrently mutated, select genes mutated in a single tumor, and select genes previously reported to be mutated in Wilms tumors were analyzed by target capture. Biological relevance was determined by features used to filter the discovery set (described above), presence of the gene in the Sanger Consensus Gene List 73 , and expression during renal development 74 .
These features are described in Supplementary Table 1 for each variant. Probes were designed and genomic DNA libraries were constructed and hybridized to the RNA baits as described 6 . Variants were called using SAMtools (v0.1.17) 75 . Variants with tumor coverage >10, tumor alternative base count >3, tumor alternative base allele frequency ≥0.05, and global minor allele frequency ≤0.01 were retained and annotated using Oncotator. Further filtering was performed on the basis of the predicted effect of the variant by multiple algorithms as described above for the discovery set. For recurrent indels, a short indel reference set was created including flanking sequences, to which we realigned all of the data to identify additional variants present below the SAMtools mpileup thresholds; identified variants were manually reviewed in IGV to confirm their presence.
Variants of interest in the discovery set that were not verified by the above methods were verified by Sanger sequencing. Primers were generated with PrimerZ, and PCR amplification was performed using Platinum Taq DNA Polymerase and Invitrogen dNTP Mix (Life Technologies Corporation) according to the manufacturer's protocol. Samples were sequenced using the Applied Biosystems DNA Sequencer (model 3730, Life Technologies Corporation) according to the manufacturer's protocol. The DNA sequence was analyzed with Chromas Lite 2.1 software (Technelysium).
Copy number analysis (discovery set). DNA labeling, hybridization, and array scanning were performed with Affymetrix 6.0 SNP arrays according to the manufacturer's protocol and processed using Affymetrix Genotyping Console (GTC) 4.0 software. Data were processed as previously described 6 . When SNP 6.0 data were not available, copy number data were calculated on the basis of the CGI relative coverage smoothed in 100-kb windows, corrected for the GC content, and normalized using composite baseline coverage from multiple healthy samples. Segments defined by a minimum of 8 probes with segment log 2 mean < −0.5 or > +0.5 were considered lost and gained, respectively, unless otherwise indicated.
Gene expression analysis (discovery set). Analysis was performed on 76 FHWT and 38 DAWT with the Affymetrix U133+2 chip according to the manufacturer's protocol and as described 6 . Gene Set Enrichment Analysis version 2.0.14 (ref. 76) was run using 1,000 permutations and phenotype permutation. Significant enrichment within the GSEA hallmark and positional gene sets was defined as FDR < 20% and P < 0.05. For unsupervised analysis, Non-negative Matrix Factorization Consensus version 5 was used 77 .
DNA methylation analysis (discovery set). Analysis was performed on 78 FHWT and 39 DAWT samples using Illumina Infinium Human Methylation 450K BeadChips according to the manufacturer's protocol, as previously described 78 . To correlate methylation and gene expression data, methylation probes located within 10,000 bp upstream and downstream of a gene were identified. For each probe and gene pair, the correlation between methylation and gene expression (using the probe with the highest expression) was determined using the General Linear Model (GLM), implemented in R. P values were adjusted for multiple comparisons using the multi-test package in R, and correlations with an adjusted P < 0.05 were considered significant. To identify particular methylation islands driving methylation patterns, the mean β value of each probe within each methylation cluster was compared with the mean β value of all remaining tumors. Those probes with a β value >0.1 in at least one comparison that were also significantly differentially methylated (q < 0.05 and FC either >1.5 or <0.5) were retained. All remaining genes with at least five differentially methylated probes were annotated with the location of the probe within the gene and the relationship of the probe within a CpG island using UCSC genome build 37. Methylation levels for all probes in imprint control regions ICR1 (IGF2-H19) and ICR2 (KCNO1-CDKN1C) were averaged. ROI was defined as 0.3-0.7 for ICR1 and ICR2, LOI as 0.8-1 for ICR1 and 0.3-0.7 for ICR2, and LOH as 0.8-1 for ICR1 and 0-0.2 for ICR2. Tumors outside of these ranges were not classified.
Computational structural analysis of mutants. Structural models for MAX, NONO and ACTB were retrieved from the Protein Data Bank. The MAP3K4 kinase domain was modeled on the basis of its 31% homology to MAP4K4 (PDB 4U3Y) using Swiss-Model 79 . Models were manually inspected, and mutations evaluated, using PyMOL.
Statistical analysis. Fisher's exact test was used to evaluate the associations between categorical variables such as between histology and the occurrence of mutations in specific genes and the co-occurrence of mutations in specific genes. P values for differential gene expression were calculated by unpaired t-test assuming unequal variance, and the two-tailed P values were reported. The correlation between methylation and gene expression was determined using the General Linear Model (GLM) implemented in R. A Life Sciences Reporting Summary for this paper is available.
Data availability. Sequencing FASTQ and BAM data files are accessible through the Database of Genotypes and Phenotypes (dbGaP phs000218). The Wilms tumor data can be found in dbGaP under accession number phs000471. Gene and miRNA expression, methylation, chromosome segmental copy number, results of sequence analysis (for example, MAF and summary files), and clinical information are available through the TARGET Data Matrix (https://ocg.cancer.gov/programs/target/data-matrix). All data sets include MIAME-and MINSEQE-compliant MAGE-TAB metadata 59 files (using v1.1 specification supporting both next-generation sequencing and microarrays, http://fged.org/projects/mage-tab/) and fully describe the methods, the specimen processing details, and the quality control parameters.
